You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

  • Technology appraisal guidance
  • Reference number: TA259
  • Published:  27 June 2012
  • Last updated:  27 July 2016
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): comments on the appraisal consultation

To follow

  • Janssen

  • The Prostate Cancer Charity

  • Prostate Cancer Support Federation

  • British Association of Urological Surgeons

  • British Uro-Oncology Group

  • Cancer Research UK

  • Royal College of Physicians

  • Department of Health

  • NHS Hertfordshire

  • NHS Bradford and Airedale

  • Commissioning Support Appraisals Service

  • National Collaborating Centre for Cancer

  • Institute of Cancer Research


This page was last updated: 18 May 2012

Back to top